Allergy Therapeutics Share Discussion Threads

[jimmyloser] 02/12/2022 08:49

Not a cat in hell's chance in my opinion. I suspect that we will all regret not filling up at this price in a few months' time.

Patience and cross your fingers impo

[jpuff] 02/12/2022 08:37

It'll probably get bought out at a fire sale price I reckon

[raleigh43] 02/12/2022 07:56

They had a set out time line for news and I remember them saying Q4 news.
It lacking is worrying?

[pfmg] 01/12/2022 14:13

well lack of news is par for the course here.

[raleigh43] 01/12/2022 11:30

And the lack of news......

[pfmg] 01/12/2022 09:07

@jimmy - exactly, I've been watching this gradual share price decrease with increasingly raised eyebrows.
Cannot figure it out unless the market is concerned as to why the previous CFO fled, with decreasing revenues are they looking perhaps to raise to fund research?

[jimmyloser] 01/12/2022 07:13

I read that Nestle are thinking about 'strategic options' for Palforzia/Aimmune who you may recall they bought for $2.6billion, this includes a sale of the business. This is because of what they called 'disappointing sales of the product.

Here we are at circa 14pence (yes, circa 14pence) and with a 'potentially' world beating peanut allergy product and add to that a world beating tree and grass product.

It makes you think!...why?

[jpuff] 10/11/2022 09:30

It's been dead money for years, no divi, no share price appreciation. What's not to like!

[jimmyloser] 08/11/2022 18:19

When the company said something about peanuts, I hadn't realised that they were referring to the share price. Oh, my days!

[genises] 03/11/2022 22:43

Agree.
You would think production would increase to make up for the missing weeks by putting extra shifts in or do they already run 24 hours a day.
I reckon they had a production problem hence complete closed down and lost stock already made but not shipped out.
It will be interesting to see the next set of accounts.
A good start for the new CO to work his magic.

[jimmyloser] 03/11/2022 19:01

More to this than meets the eyes impo

[jpuff] 03/11/2022 18:56

Incompetent useless man who are just interested in drawing their salaries rather than building wealth for shareholders

[red army] 03/11/2022 16:58

I agree - if youre about to shutdown production you make darn sure that you boos production before and increase stock levels so that customers are not effected.
Its pretty basic stuff.

[richsawko] 03/11/2022 15:06

I presume you mean 2023? I have wished this for the last 15 years but it never seems to happen

[genises] 03/11/2022 15:00

No surprise in seeing the price go down with reduced profits for next year.
one has to ask why the company could had not for see a production halt and increased the amount of shifts to weekends before stoppage.
Poor management at the top.
But future could look very promising in 2013

[jpuff] 03/11/2022 12:30

It's a waste of time these past five years

[richsawko] 03/11/2022 09:17

Not looking good

[richtea2517] 03/11/2022 09:09

Are we pulling the plug on this ?

[qackers] 01/11/2022 17:36

You've earned it

[qackers] 01/11/2022 17:35

Jimmyloser. Remember Medisys. You do pick them although that one came good I seem to remember?
May I respectively request a name change to Jimmywinner. You've earnt it.

[amishp67] 01/11/2022 15:11

What happened?

[jimmyloser] 01/11/2022 11:39

Words fail me................what did I do to deserve this?

[amishp67] 28/10/2022 08:40

https://ichgcp.net/clinical-trials-registry/research/list?term=Vlp+peanut

[wizzkid211] 28/10/2022 06:58

Allergy Therapeutics PLC Allergy to resume UK manufacturing production
28/10/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Friday 28 October 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 4690E

Allergy Therapeutics PLC

28 October 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics to resume UK manufacturing production in mid-November

28(th) October 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergen immunotherapy, today announces that it will resume production at the Freeman facility, part of its Worthing, UK manufacturing site, on 14(th) November.

The Group announced a short-term voluntary pause in production following an internal review of its current operating processes. This pause was part of the Group's previously communicated ongoing programme to improve the robustness of its quality systems and build capacity across its manufacturing facilities but was accelerated when it became clear that the capacity was unable to cope with the commercial demand.

The pause in manufacturing occurred during a period of peak production prior to the start of the pollen season in the spring. As a consequence, whilst it is too early to determine the exact impact, it is currently estimated that revenue will be between approximately 13% and 18% lower than market expectations of circa GBP80m at current exchange rates for the year ended 30 June 2023. Business expenses for the same period are currently expected to reduce by around GBP3m.

Work is continuing to further minimise the impact through cost control and tight working capital management and delay in non-critical capital spend.

At the expected reduced levels of underlying profit, excluding research and development costs, the terms of the NatWest revolving credit facility would not allow use of the facility.

Manuel Llobet, CEO at Allergy Therapeutics , stated: "We took the difficult decision to temporarily pause production at the Freeman facility to continue delivering the highest standards of quality systems. We are now pleased to have a clear timeline to resume our UK manufacturing activities."

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

- ENDS -

[jimmyloser] 28/10/2022 06:06

If ever a share was a barrel of fun to own, then it is certainly this one.
Oh yes indeed.